Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig - Тофацитиниб - artritis, reumatoidni - imunosupresivi - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 i 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pfizer bh d.o.o. sarajevo - тофацитиниб - filmom obložena tableta - 5 mg/1 tableta - 1 filmom obložena tableta sadrži: 5 mg tofacitiniba (u obliku tofacitinib citrata)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pfizer bh d.o.o. sarajevo - тофацитиниб - filmom obložena tableta - 10 mg/1 tableta - 1 filmom obložena tableta sadrži: 10 mg tofacitiniba (u obliku tofacitinib citrata)

Hrvatska - hrvatski - Ecolab

ecolab deutschland gmbh -

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

baxter d.o.o., letališka cesta 29a, ljubljana, slovenija - natrijev klorid kalijev klorid magnezijev klorid heksahidrat natrijev acetat trihidrat natrijev glukonat - otopina za infuziju - 5,26 g/l + 0,37 g/l + 0,30 g/l + 3,68 g/l + 5,02 g/l - urbroj: 1000 ml otopine za infuziju sadrži 5,26 g natrijeva klorida, 0,37 g kalijeva klorida, 0,30 g magnezijeva klorid heksahidrata, 3,68 g natrijeva acetat trihidrata, 5,02 g natrijeva glukonata

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

richter pharma ag, feldgasse 19, 4600 wels, austrija - metamizolnatrij; kofein; kalcijev glukonat za injekciju; magnezijev glukonat; natrijev dihidrogenfosfat dihidrat; acetilmetionin; glukoza hidrat - otopina za infuziju - analgetici - konja, goveda i svinja

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

vetviva richter gmbh, durisolstrasse 14, 4600 wels, austrija - metamizolnatrij; kofein; kalcijev glukonat za injekciju; magnezijev glukonat; natrijev dihidrogenfosfat dihidrat; acetilmetionin; glukoza hidrat - otopina za infuziju - konja, goveda i svinja

Hrvatska - hrvatski - Ecolab

ecolab deutschland gmbh -

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastična sredstva - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.